Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of epilepsy with uncontrolled partial onset seizures, whether or not secondarily generalized, and the diagnosis was \>= 6 months before the Selection Visit~* epilepsy was classifiable according to the ILAE Classification~* \>= 4 partial onset seizures during the 4 weeks preceding the Selection Visit and were required to have \>= 4 partial onset seizures during each 4-week interval of the Baseline Period to qualify for randomization~* unsatisfactory current AED treatment in terms of efficacy and/or safety~* stable AED treatment consisting of no more than two AEDs~Exclusion Criteria:~* treatable seizure etiology~* epilepsy secondary to a progressive cerebral disease or any other progressively neurodegenerative disease, including Rasmussen and Landau-Kleffner diseases~* history of status epilepticus which required hospitalization during 3 months prior to the Selection Visit~* history of or the presence of pseudo seizures~* current diagnosis of Lennox-Gastaut syndrome

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Levetiracetam (LEV) (Type: EXPERIMENTAL): LEV dose was titrated to a level of 60 mg/kg/day. The initial dose level was 20 mg/kg/day for the first two weeks, followed by a dose level of 40 mg/kg/day for two weeks. If lower doses were well tolerated, the LEV dose was increased to a dose level of 60 mg/kg/day for the remaining 10 weeks. The dose level could be reduced to 40 mg/kg/day if the patient did not tolerate LEV at a dose level of 60 mg/kg/day.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects received Placebo matching to LEV treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).